Compare BioNTech SE - ADR (BNTX) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Estee Lauder Companies Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Estee Lauder Companies Inc trades at $81.04 (market cap $29.25B). The key difference: Estee Lauder Companies Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.73% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | EL | |
|---|---|---|
Market Cap | $22.86B | $29.25B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $119.61 |
52-Week Low | $83.89 | $67.23 |
Enterprise Value | $6.53B | $35.43B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Estée Lauder (EL) trades at $81.15, down 1.83% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows negative net income and declining revenue trends, though recent quarters have beaten EPS estimates. Analyst consensus is divided with a $90.60 price target, while technical indicators point to support near $80.
Outlook remains cautious due to profitability challenges and competitive pressures, but potential upside exists if cost controls and innovation drive margin recovery. Key risks include sustained earnings pressure and macroeconomic sensitivity in the beauty sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
